[go: up one dir, main page]

PE20081409A1 - Antagonistas del receptor de progesterona - Google Patents

Antagonistas del receptor de progesterona

Info

Publication number
PE20081409A1
PE20081409A1 PE2007001568A PE2007001568A PE20081409A1 PE 20081409 A1 PE20081409 A1 PE 20081409A1 PE 2007001568 A PE2007001568 A PE 2007001568A PE 2007001568 A PE2007001568 A PE 2007001568A PE 20081409 A1 PE20081409 A1 PE 20081409A1
Authority
PE
Peru
Prior art keywords
receptor antagonists
progesterone receptor
17alfa
11beta
pregna
Prior art date
Application number
PE2007001568A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Anja Schmidt
Arwed Cleve
Orlin Petrov
Gunnar Garke
Stefan Pruhs
Margarete Brudny-Kloppel
Antje Rottmann
Rainer Hasselmann
Marcus Schultze-Mosgau
Carsten Moller
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20081409A1 publication Critical patent/PE20081409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE PREGNADIENONA DE FORMULA (I), DONDE R1 Y R2 SON OH O R1 Y R2 JUNTOS PUEDEN SER UN GRUPO OXO. SON COMPUESTOS PREFERIDOS: 11BETA-[4-(1,2-DIHIDROXIETIL)FENIL]-20,20,21,21,21-PENTAFLUORO-17-HIDROXI-19-NOR-17ALFA-PREGNA-4,9-DIEN-3-ONA, 20,20,21,21,21-PENTAFLUORO-17-HIDROXI-11BETA-[4-(HIDROXIACETIL)FENIL]-19-NOR-17ALFA-PREGNA-4,9-DIEN-3-ONA, ENTRE OTROS. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE PROGESTERONA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES GINECOLOGICAS
PE2007001568A 2006-11-15 2007-11-14 Antagonistas del receptor de progesterona PE20081409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006054535A DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten

Publications (1)

Publication Number Publication Date
PE20081409A1 true PE20081409A1 (es) 2008-12-05

Family

ID=39243738

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001568A PE20081409A1 (es) 2006-11-15 2007-11-14 Antagonistas del receptor de progesterona

Country Status (40)

Country Link
US (1) US8053426B2 (es)
EP (1) EP2081951B1 (es)
JP (1) JP5260537B2 (es)
KR (1) KR101494914B1 (es)
CN (1) CN101541823B (es)
AR (1) AR063813A1 (es)
AT (1) ATE465169T1 (es)
AU (1) AU2007321848B2 (es)
BR (1) BRPI0718409A2 (es)
CA (1) CA2669767C (es)
CL (1) CL2007003266A1 (es)
CO (1) CO6180443A2 (es)
CY (1) CY1110671T1 (es)
DE (2) DE102006054535A1 (es)
DK (1) DK2081951T3 (es)
EA (1) EA017038B1 (es)
EC (1) ECSP099337A (es)
ES (1) ES2343915T3 (es)
GT (1) GT200900128A (es)
HN (1) HN2009000997A (es)
HR (1) HRP20100366T1 (es)
IL (1) IL198650A (es)
JO (1) JO2672B1 (es)
MA (1) MA30990B1 (es)
MX (1) MX2009005212A (es)
NO (1) NO20092284L (es)
NZ (1) NZ576927A (es)
PA (1) PA8755801A1 (es)
PE (1) PE20081409A1 (es)
PL (1) PL2081951T3 (es)
PT (1) PT2081951E (es)
RS (1) RS51369B (es)
SI (1) SI2081951T1 (es)
SV (1) SV2009003260A (es)
TN (1) TN2009000185A1 (es)
TW (1) TW200831109A (es)
UA (1) UA98312C2 (es)
UY (1) UY30718A1 (es)
WO (1) WO2008058767A1 (es)
ZA (1) ZA200904150B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
MX391191B (es) 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
JP2018528944A (ja) 2015-09-25 2018-10-04 コンテクスト バイオファーマ インコーポレイテッド オナプリストン中間体の製造方法
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
US20170266204A1 (en) * 2016-03-21 2017-09-21 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
CN86102502B (zh) * 1986-08-29 1988-06-22 上海市计划生育科学研究所 11，17位双取代δ4，9-雌甾二烯化合物的合成方法
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19535572B4 (de) * 1994-09-14 2007-02-01 Schering Ag Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen
DK0792152T3 (da) * 1994-11-22 2004-07-12 Balance Pharmaceuticals Inc Fremgangsmåder til svangerskabsforebyggelse
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) * 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
ES2272561T3 (es) * 2000-10-18 2007-05-01 Schering Aktiengesellschaft Inhibicion de dependencia de factores de crecimiento de la celulas tumorales.
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DE50301507D1 (de) 2002-05-03 2005-12-01 Schering Ag 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
EA200900635A1 (ru) 2009-12-30
DK2081951T3 (da) 2010-08-09
DE602007006040D1 (de) 2010-06-02
GT200900128A (es) 2012-02-01
IL198650A0 (en) 2010-02-17
CA2669767C (en) 2014-04-01
PA8755801A1 (es) 2009-08-26
US20080200440A1 (en) 2008-08-21
MA30990B1 (fr) 2009-12-01
AU2007321848B2 (en) 2013-09-19
AR063813A1 (es) 2009-02-18
BRPI0718409A2 (pt) 2013-12-17
EP2081951B1 (en) 2010-04-21
NZ576927A (en) 2012-01-12
IL198650A (en) 2012-05-31
JP5260537B2 (ja) 2013-08-14
NO20092284L (no) 2009-08-13
KR101494914B1 (ko) 2015-02-23
HRP20100366T1 (hr) 2010-07-31
HK1136302A1 (en) 2010-06-25
KR20090079995A (ko) 2009-07-22
JO2672B1 (en) 2012-06-17
TW200831109A (en) 2008-08-01
US8053426B2 (en) 2011-11-08
CY1110671T1 (el) 2015-06-10
DE102006054535A1 (de) 2008-05-21
AU2007321848A1 (en) 2008-05-22
HN2009000997A (es) 2011-10-19
ES2343915T3 (es) 2010-08-12
JP2010509386A (ja) 2010-03-25
PL2081951T3 (pl) 2010-09-30
UA98312C2 (en) 2012-05-10
CO6180443A2 (es) 2010-07-19
WO2008058767A1 (en) 2008-05-22
RS51369B (sr) 2011-02-28
CL2007003266A1 (es) 2008-07-04
ATE465169T1 (de) 2010-05-15
CN101541823B (zh) 2012-10-03
SI2081951T1 (sl) 2010-08-31
PT2081951E (pt) 2010-07-01
MX2009005212A (es) 2009-05-27
CN101541823A (zh) 2009-09-23
ECSP099337A (es) 2009-06-30
UY30718A1 (es) 2008-07-03
EP2081951A1 (en) 2009-07-29
ZA200904150B (en) 2010-11-24
SV2009003260A (es) 2009-12-14
TN2009000185A1 (en) 2010-10-18
EA017038B1 (ru) 2012-09-28
CA2669767A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
PE20081409A1 (es) Antagonistas del receptor de progesterona
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
PE20070335A1 (es) Benzimidazoles sustituidos y metodos para su preparacion
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ECSP088820A (es) Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p.
NO20072435L (no) CGRP-reseptorantagonister
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ATE537170T1 (de) Cgrp-rezeptorantagonisten
GEP20115140B (en) Substituted spirocyclic cgrp receptor antagonists
AR047529A1 (es) Compuestos de quinolina sustituidos
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
UA90706C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
CL2008003182A1 (es) Compuestos derivados de 1,2,4-triazol-3-amino; composicion farmaceutica; y su uso en el tratamiento del dolor, reflujo gastroesofagico, ansiedad, sindrome del intestino irritable.
ATE466853T1 (de) Cgrp-rezeptorantagonisten
ATE507880T1 (de) Cgrp-rezeptorantagonisten
MX2007004661A (es) Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3.
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
PE20120082A1 (es) Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed